Literature DB >> 20705309

The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.

Georget Y Reaiche1, Marc F Le Mire, William S Mason, Allison R Jilbert.   

Abstract

Residual hepatitis B virus (HBV) DNA can be detected following the resolution of acute HBV infection. Our previous work using duck hepatitis B virus (DHBV) infected ducks, indicated that ~80% of residual DHBV DNA in the liver is in the covalently closed circular DNA (cccDNA) form, suggesting that viral DNA synthesis is suppressed. The current study asked more directly if maintenance of residual DHBV cccDNA is dependent upon ongoing viral DNA synthesis. Ducks that recovered from acute DHBV infection were divided into 2 groups and treated with the antiviral drug, Entecavir (ETV), or placebo. No major differences in the stability of cccDNA or levels of residual cccDNA were observed in liver biopsy tissues taken 95 days apart from ETV treated and placebo control ducks. The data suggest that residual DHBV cccDNA is highly stable and present in a cell population with a rate of turnover similar to normal, uninfected hepatocytes.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20705309     DOI: 10.1016/j.virol.2010.07.013

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  A high level of mutation tolerance in the multifunctional sequence encoding the RNA encapsidation signal of an avian hepatitis B virus and slow evolution rate revealed by in vivo infection.

Authors:  Bernadette Schmid; Christine Rösler; Michael Nassal
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 2.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

Review 3.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

4.  Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.

Authors:  Muhammad Sheraz; Junjun Cheng; Liudi Tang; Jinhong Chang; Ju-Tao Guo
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

5.  Determine the structure of phosphorylated modification of icariin and its antiviral activity against duck hepatitis virus A.

Authors:  Wen Xiong; Xia Ma; Yi Wu; Yun Chen; Ling Zeng; Jiaguo Liu; Weidong Sun; Deyun Wang; Yuanliang Hu
Journal:  BMC Vet Res       Date:  2015-08-14       Impact factor: 2.741

Review 6.  Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.

Authors:  Hung-Chih Yang; Jia-Horng Kao
Journal:  Emerg Microbes Infect       Date:  2014-09-17       Impact factor: 7.163

7.  Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs.

Authors:  Feng Li; Liang Cheng; Christopher M Murphy; Natalia J Reszka-Blanco; Yaxu Wu; Liqun Chi; Jianming Hu; Lishan Su
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

8.  Simple and Reliable Method to Quantify the Hepatitis B Viral Load and Replicative Capacity in Liver Tissue and Blood Leukocytes.

Authors:  Claudia Minosse; Sabrina Coen; Ubaldo Visco Comandini; Raffaella Lionetti; Marzia Montalbano; Stefano Cerilli; Donatella Vincenti; Andrea Baiocchini; Maria R Capobianchi; Stefano Menzo
Journal:  Hepat Mon       Date:  2016-02-29       Impact factor: 0.660

9.  Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.

Authors:  Faseeha Noordeen; Catherine A Scougall; Arend Grosse; Qiao Qiao; Behzad B Ajilian; Georget Reaiche-Miller; John Finnie; Melanie Werner; Ruth Broering; Joerg F Schlaak; Andrew Vaillant; Allison R Jilbert
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

Review 10.  Therapeutic strategies for a functional cure of chronic hepatitis B virus infection.

Authors:  Jinhong Chang; Fang Guo; Xuesen Zhao; Ju-Tao Guo
Journal:  Acta Pharm Sin B       Date:  2014-06-18       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.